Virios Therapeutics Llc
Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for… Read more
Virios Therapeutics Llc (VIRI) - Net Assets
Latest net assets as of June 2024: $3.14 Million USD
Based on the latest financial reports, Virios Therapeutics Llc (VIRI) has net assets worth $3.14 Million USD as of June 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($3.64 Million) and total liabilities ($500.07K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $3.14 Million |
| % of Total Assets | 86.25% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 1.45 |
Virios Therapeutics Llc - Net Assets Trend (2018–2023)
This chart illustrates how Virios Therapeutics Llc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Virios Therapeutics Llc (2018–2023)
The table below shows the annual net assets of Virios Therapeutics Llc from 2018 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | $3.81 Million | -48.04% |
| 2022-12-31 | $7.33 Million | -49.48% |
| 2021-12-31 | $14.50 Million | -51.57% |
| 2020-12-31 | $29.94 Million | +705.78% |
| 2019-12-31 | $-4.94 Million | -292.14% |
| 2018-12-31 | $-1.26 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Virios Therapeutics Llc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 4632413900.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.93K | 0.05% |
| Other Components | $65.27 Million | 1714.63% |
| Total Equity | $3.81 Million | 100.00% |
Virios Therapeutics Llc Competitors by Market Cap
The table below lists competitors of Virios Therapeutics Llc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
PHILOGEN S.P.A.
F:78Q
|
$206.57K |
|
Penn Bancshares Inc
PINK:PEBA
|
$206.58K |
|
MS&AD INSURANCE
MU:59M
|
$206.63K |
|
DDFO
BATS:DDFO
|
$206.73K |
|
OCEANEERING INTL
BE:OII
|
$206.36K |
|
IRACX
NMFQS:IRACX
|
$206.32K |
|
REGIONS FINANCIAL (RN7.SG)
STU:RN7
|
$206.22K |
|
Antiaging Quantum Living Inc.
PINK:AAQL
|
$206.17K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Virios Therapeutics Llc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 7,326,494 to 3,806,894, a change of -3,519,600 (-48.0%).
- Net loss of 5,296,015 reduced equity.
- New share issuances of 1,070,448 increased equity.
- Other factors increased equity by 705,967.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-5.30 Million | -139.12% |
| Share Issuances | $1.07 Million | +28.12% |
| Other Changes | $705.97K | +18.54% |
| Total Change | $- | -48.04% |
Book Value vs Market Value Analysis
This analysis compares Virios Therapeutics Llc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 11.69x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $-0.26 | $2.37 | x |
| 2019-12-31 | $-0.60 | $2.37 | x |
| 2020-12-31 | $3.61 | $2.37 | x |
| 2021-12-31 | $1.74 | $2.37 | x |
| 2022-12-31 | $0.66 | $2.37 | x |
| 2023-12-31 | $0.20 | $2.37 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Virios Therapeutics Llc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -139.12%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.09x
- Recent ROE (-139.12%) is below the historical average (-75.00%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.99 Million |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.27 Million |
| 2020 | -34.56% | 0.00% | 0.00x | 1.05x | $-13.34 Million |
| 2021 | -110.06% | 0.00% | 0.00x | 1.09x | $-17.41 Million |
| 2022 | -166.25% | 0.00% | 0.00x | 1.14x | $-12.91 Million |
| 2023 | -139.12% | 0.00% | 0.00x | 1.09x | $-5.68 Million |
Industry Comparison
This section compares Virios Therapeutics Llc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Virios Therapeutics Llc (VIRI) | $3.14 Million | 0.00% | 0.16x | $206.50K |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |